ARQT Arcutis Biotherapeutics, Inc.
FY2025 10-K
Arcutis Biotherapeutics, Inc. (ARQT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Commercial-stage biopharma specializing in differentiated topical and systemic dermatology treatments targeting immune-mediated diseases
- • New approvals: ZORYVE foam 0.3% for seborrheic dermatitis (FDA Dec 2023), scalp/body plaque psoriasis (FDA May 2025); ZORYVE cream 0.15% for atopic dermatitis (FDA July 2024); ZORYVE cream 0.05% for ages 2-5 (FDA Oct 2025)
Management Discussion & Analysis
- • Revenue $372.1M in 2025, up 123% YoY from $166.5M in 2024; ZORYVE foam up $110.4M, cream 0.15% up $58.4M, cream 0.3% up $35.9M
- • Operating expenses increased; R&D $77.1M in 2025 vs $76.4M 2024 (+1%), SG&A up by $45.2M driven by sales/marketing and compensation
Risk Factors
- • Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures
- • Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management
Financial SummaryXBRL
Revenue
$376M
Net Income
-$16M
Operating Margin
-3.3%
Net Margin
-4.3%
ROE
-8.5%
Total Assets
$433M
EPS (Diluted)
$-0.13
Operating Cash Flow
-$6M
Source: XBRL data from Arcutis Biotherapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Arcutis Biotherapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.